Content
September 2017, Volume 35, Issue 9
- 859-866 Using Discrete Choice Experiments to Inform the Benefit-Risk Assessment of Medicines: Are We Ready Yet?
by Caroline M. Vass & Katherine Payne - 867-877 Informing Reimbursement Decisions Using Cost-Effectiveness Modelling: A Guide to the Process of Generating Elicited Priors to Capture Model Uncertainties
by Laura Bojke & Bogdan Grigore & Dina Jankovic & Jaime Peters & Marta Soares & Ken Stein - 879-893 Cost-Effectiveness of Drug Treatments for Advanced Melanoma: A Systematic Literature Review
by Darío Rubio-Rodríguez & Silvia Diego Blanco & Maite Pérez & Carlos Rubio-Terrés - 895-908 Health-Related Resource-Use Measurement Instruments for Intersectoral Costs and Benefits in the Education and Criminal Justice Sectors
by Susanne Mayer & Aggie T. G. Paulus & Agata Łaszewska & Judit Simon & Ruben M. W. A. Drost & Dirk Ruwaard & Silvia M. A. A. Evers - 909-919 Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Philip Morgan & Nerys Woolacott & Mousumi Biswas & Teumzghi Mebrahtu & Melissa Harden & Robert Hodgson - 921-936 The Cost of Relapse in Schizophrenia
by Mark Pennington & Paul McCrone - 937-949 Simulation Modelling in Healthcare: An Umbrella Review of Systematic Literature Reviews
by Syed Salleh & Praveen Thokala & Alan Brennan & Ruby Hughes & Andrew Booth - 951-962 Using Parameter Constraints to Choose State Structures in Cost-Effectiveness Modelling
by Howard Thom & Chris Jackson & Nicky Welton & Linda Sharples - 963-963 Erratum to: Using Parameter Constraints to Choose State Structures in Cost-Effectiveness Modelling
by Howard Thom & Chris Jackson & Nicky Welton & Linda Sharples - 965-974 Distribution-Weighted Cost-Effectiveness Analysis Using Lifetime Health Loss
by Ulrikke J. V. Hernæs & Kjell A. Johansson & Trygve Ottersen & Ole F. Norheim - 975-976 Ahead of Our Time: Collaboration in Modeling Then and Now
by Renée J. G. Arnold & Sean Ekins
August 2017, Volume 35, Issue 8
- 755-757 Sharing is Caring: The Case for Company-Level Collaboration in Pharmacoeconomic Modelling
by Anthony J. Hatswell & Fleur Chandler - 759-765 Evaluation of Healthcare Interventions and Big Data: Review of Associated Data Issues
by Carl V. Asche & Brian Seal & Kristijan H. Kahler & Elisabeth M. Oehrlein & Meredith Greer Baumgartner - 767-776 How to Appropriately Extrapolate Costs and Utilities in Cost-Effectiveness Analysis
by Laura Bojke & Andrea Manca & Miqdad Asaria & Ronan Mahon & Shijie Ren & Stephen Palmer - 777-791 Defining and Measuring the Affordability of New Medicines: A Systematic Review
by Fernando Antoñanzas & Robert Terkola & Paul M. Overton & Natalie Shalet & Maarten Postma - 793-804 Does the Public Prefer Health Gain for Cancer Patients? A Systematic Review of Public Views on Cancer and its Characteristics
by Liz Morrell & Sarah Wordsworth & Sian Rees & Richard Barker - 805-815 Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Paul Tappenden & Christopher Carroll & John W. Stevens & Andrew Rawdin & Sabine Grimm & Mark Clowes & Eva Kaltenthaler & John R. Ingram & Fiona Collier & Mohammad Ghazavi - 817-830 A Comparison of Four Software Programs for Implementing Decision Analytic Cost-Effectiveness Models
by Chase Hollman & Mike Paulden & Petros Pechlivanoglou & Christopher McCabe - 831-844 Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States
by Min Huang & Yanyan Lou & James Pellissier & Thomas Burke & Frank Xiaoqing Liu & Ruifeng Xu & Vamsidhar Velcheti - 845-858 Using Genomic Information to Guide Ibrutinib Treatment Decisions in Chronic Lymphocytic Leukaemia: A Cost-Effectiveness Analysis
by James Buchanan & Sarah Wordsworth & Ruth Clifford & Pauline Robbe & Jenny C. Taylor & Anna Schuh & Samantha J. L. Knight
July 2017, Volume 35, Issue 7
- 669-672 Defining Value: The Need for a Longer, Broader View
by Tomas J. Philipson & Sachin Kamal-Bahl & Anupam B. Jena - 673-683 Verification of Decision-Analytic Models for Health Economic Evaluations: An Overview
by Erik J. Dasbach & Elamin H. Elbasha - 685-695 Regression-Based Approaches to Patient-Centered Cost-Effectiveness Analysis
by Daisuke Goto & Ya-Chen Tina Shih & Pascal Lecomte & Melvin Olson & Chukwukadibia Udeze & Yujin Park & C. Daniel Mullins - 697-716 Discrete Choice Experiments: A Guide to Model Specification, Estimation and Software
by Emily Lancsar & Denzil G. Fiebig & Arne Risa Hole - 717-726 Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Lesley Uttley & Sophie Whyte & Timothy Gomersall & Shijie Ren & Ruth Wong & Duncan Chambers & Paul Tappenden - 727-740 Emerging Use of Early Health Technology Assessment in Medical Product Development: A Scoping Review of the Literature
by Maarten J. IJzerman & Hendrik Koffijberg & Elisabeth Fenwick & Murray Krahn - 741-753 An Investigation of the Overlap Between the ICECAP-A and Five Preference-Based Health-Related Quality of Life Instruments
by Lidia Engel & Duncan Mortimer & Stirling Bryan & Scott A. Lear & David G. T. Whitehurst
June 2017, Volume 35, Issue 6
- 607-612 How Qualitative Methods Can be Used to Inform Model Development
by Samantha Husbands & Susan Jowett & Pelham Barton & Joanna Coast - 613-624 Bayesian Methods for Calibrating Health Policy Models: A Tutorial
by Nicolas A. Menzies & Djøra I. Soeteman & Ankur Pandya & Jane J. Kim - 637-646 Are Quality-Adjusted Life Years a Good Proxy Measure of Individual Capabilities?
by Paul Mark Mitchell & Sridhar Venkatapuram & Jeff Richardson & Angelo Iezzi & Joanna Coast - 647-659 An Early Health Economic Analysis of the Potential Cost Effectiveness of an Adherence Intervention to Improve Outcomes for Patients with Cystic Fibrosis
by Paul Tappenden & Susannah Sadler & Martin Wildman - 661-663 Comment on: “Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal”
by Odette Reifsnider & Fiona Hall & Sonja Sorensen & Irina Proskorovsky & Isabelle Girod & Jennifer Lee - 665-667 Response to Letter to the Editor Regarding “Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal”
by Bram L. T. Ramaekers & Rob Riemsma & Florian Tomini & Thea Asselt & Sohan Deshpande & Steven Duffy & Nigel Armstrong & Johan L. Severens & Jos Kleijnen & Manuela A. Joore
May 2017, Volume 35, Issue 5
- 493-500 Pharmacy Benefit Management Companies: Do They Create Value in the US Healthcare System?
by Alan Lyles - 501-515 Methodological Issues Surrounding the Use of Baseline Health-Related Quality of Life Data to Inform Trial-Based Economic Evaluations of Interventions Within Emergency and Critical Care Settings: A Systematic Literature Review
by Melina Dritsaki & Felix Achana & James Mason & Stavros Petrou - 517-535 Economic Evaluations of New Oral Anticoagulants for the Prevention of Venous Thromboembolism After Total Hip or Knee Replacement: A Systematic Review
by James Brockbank & Sorrel Wolowacz - 537-547 Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Christopher Carroll & Paul Tappenden & Rachid Rafia & Jean Hamilton & Duncan Chambers & Mark Clowes & Paul Durrington & Nadeem Qureshi & Anthony S. Wierzbicki - 549-559 Can Mapping Algorithms Based on Raw Scores Overestimate QALYs Gained by Treatment? A Comparison of Mappings Between the Roland–Morris Disability Questionnaire and the EQ-5D-3L Based on Raw and Differenced Score Data
by Jason Madan & Kamran A. Khan & Stavros Petrou & Sarah E. Lamb - 561-573 Economic Evaluations Alongside Efficient Study Designs Using Large Observational Datasets: the PLEASANT Trial Case Study
by Matthew Franklin & Sarah Davis & Michelle Horspool & Wei Sun Kua & Steven Julious - 575-589 The Potential Cost Effectiveness of Different Dengue Vaccination Programmes in Malaysia: A Value-Based Pricing Assessment Using Dynamic Transmission Mathematical Modelling
by Asrul Akmal Shafie & Hui Yee Yeo & Laurent Coudeville & Lucas Steinberg & Balvinder Singh Gill & Rohani Jahis & Amar-Singh HSS - 591-601 Making Implicit Assumptions Explicit in the Costing of Informal Care: The Case of Head and Neck Cancer in Ireland
by Paul Hanly & Rebecca Maguire & Myles Balfe & Eleanor O’Sullivan & Linda Sharp - 603-604 Comment on: “Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation”
by Afschin Gandjour - 605-606 Authors’ Reply to Gandjour: “Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation”
by Monika Wagner & Mireille Goetghebeur
April 2017, Volume 35, Issue 4
- 397-413 Economic Studies in Motor Neurone Disease: A Systematic Methodological Review
by Alan Moore & Carolyn A. Young & Dyfrig A. Hughes - 415-424 Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Benjamin Kearns & Abdullah Pandor & Matt Stevenson & Jean Hamilton & Duncan Chambers & Mark Clowes & John Graham & M. Satish Kumar - 425-438 Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma
by Kelly Fust & Xiaoyan Li & Michael Maschio & Guillermo Villa & Anju Parthan & Richard Barron & Milton C. Weinstein & Luc Somers & Caroline Hoefkens & Gary H. Lyman - 439-451 Is Dimension Order Important when Valuing Health States Using Discrete Choice Experiments Including Duration?
by Brendan Mulhern & Richard Norman & Paula Lorgelly & Emily Lancsar & Julie Ratcliffe & John Brazier & Rosalie Viney - 453-467 Mapping CHU9D Utility Scores from the PedsQLTM 4.0 SF-15
by Christine Mpundu-Kaambwa & Gang Chen & Remo Russo & Katherine Stevens & Karin Dam Petersen & Julie Ratcliffe - 469-478 Measuring Care-Related Quality of Life of Caregivers for Use in Economic Evaluations: CarerQol Tariffs for Australia, Germany, Sweden, UK, and US
by Renske J. Hoefman & Job Exel & Werner B. F. Brouwer - 479-491 A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK
by C. Rinciog & M. Watkins & S. Chang & T. M. Maher & C. LeReun & D. Esser & A. Diamantopoulos
March 2017, Volume 35, Issue 3
- 259-269 Weighing Clinical Evidence Using Patient Preferences: An Application of Probabilistic Multi-Criteria Decision Analysis
by Henk Broekhuizen & Maarten J. IJzerman & A. Brett Hauber & Catharina G. M. Groothuis-Oudshoorn - 271-296 A Systematic Review and Critical Appraisal of Economic Evaluations of Pharmacological Interventions for People with Bipolar Disorder
by Ifigeneia Mavranezouli & Joran Lokkerbol - 297-318 A Systematic Review of Cardiovascular Outcomes-Based Cost-Effectiveness Analyses of Lipid-Lowering Therapies
by Ching-Yun Wei & Ruben G. W. Quek & Guillermo Villa & Shravanthi R. Gandra & Carol A. Forbes & Steve Ryder & Nigel Armstrong & Sohan Deshpande & Steven Duffy & Jos Kleijnen & Peter Lindgren - 319-329 How Consistent is the Relationship between Improved Glucose Control and Modelled Health Outcomes for People with Type 2 Diabetes Mellitus? a Systematic Review
by Xinyang Hua & Thomas Wai-Chun Lung & Andrew Palmer & Lei Si & William H. Herman & Philip Clarke - 331-345 The Valuation of Informal Care in Cost-of-Illness Studies: A Systematic Review
by Juan Oliva-Moreno & Marta Trapero-Bertran & Luz Maria Peña-Longobardo & Raúl del Pozo-Rubio - 347-362 Valuing Meta-Health Effects for Use in Economic Evaluations to Inform Reimbursement Decisions: A Review of the Evidence
by Richard Abreu Lourenco & Marion Haas & Jane Hall & Rosalie Viney - 363-373 Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30 % Bone Marrow Blasts: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal
by Irina A. Tikhonova & Martin W. Hoyle & Tristan M. Snowsill & Chris Cooper & Joanna L. Varley-Campbell & Claudius E. Rudin & Ruben E. Mujica Mota - 375-396 Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM)
by Michael Willis & Pierre Johansen & Andreas Nilsson & Christian Asseburg
February 2017, Volume 35, Issue 2
- 129-139 Emergent Challenges in Determining Costs for Economic Evaluations
by Josephine C. Jacobs & Paul G. Barnett - 141-162 Systematic Review of the Cost Effectiveness of Insulin Analogues in Type 1 and Type 2 Diabetes Mellitus
by Asrul Akmal Shafie & Chin Hui Ng & Yui Ping Tan & Nathorn Chaiyakunapruk - 163-176 Economic Evaluations of Pharmaceuticals Granted a Marketing Authorisation Without the Results of Randomised Trials: A Systematic Review and Taxonomy
by Anthony J. Hatswell & Nick Freemantle & Gianluca Baio - 177-190 Pharmacoeconomic Considerations in Treating Actinic Keratosis: An Update
by Spencer M. Vale & Dane Hill & Steven R. Feldman - 191-202 Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal
by Bram L. T. Ramaekers & Rob Riemsma & Florian Tomini & Thea Asselt & Sohan Deshpande & Steven Duffy & Nigel Armstrong & Johan L. Severens & Jos Kleijnen & Manuela A. Joore - 203-213 A Review of Ruxolitinib for the Treatment of Myelofibrosis: A Critique of the Evidence
by Ros Wade & Robert Hodgson & Mousumi Biswas & Melissa Harden & Nerys Woolacott - 215-223 A Review of US Drug Costs Relevant to Medicare, Medicaid, and Commercial Insurers Post-Affordable Care Act Enactment, 2010–2016
by Jacquelyn McRae & F. Randy Vogenberg & Silky Webb Beaty & Elizabeth Mearns & Stefan Varga & Laura Pizzi - 225-235 Cost Effectiveness of Naloxegol for Opioid-Induced Constipation in the UK
by Richard Lawson & James Ryan & Frederic King & Jo Wern Goh & Eszter Tichy & Kevin Marsh - 237-248 Simulation Modelling in Ophthalmology: Application to Cost Effectiveness of Ranibizumab and Aflibercept for the Treatment of Wet Age-Related Macular Degeneration in the United Kingdom
by Lindsay Claxton & Robert Hodgson & Matthew Taylor & Bill Malcolm & Ruth Pulikottil Jacob - 249-258 Economic Evaluation in Duchenne Muscular Dystrophy: Model Frameworks for Cost-Effectiveness Analysis
by Erik Landfeldt & Lars Alfredsson & Volker Straub & Hanns Lochmüller & Katharine Bushby & Peter Lindgren
December 2017, Volume 35, Issue 1
- 1-3 Heath State Utility Values for Cost-Effectiveness Models
by Jonathan Karnon - 5-6 Special Edition on Utility Measurement, PharmacoEconomics
by Andrew Lloyd - 7-9 Sourcing and Using Appropriate Health State Utility Values in Economic Models in Health Care
by Roberta Ara & Tessa Peasgood & Clara Mukuria & Helene Chevrou-Severac & Donna Rowen & Ismail Azzabi-Zouraq & Suzy Paisley & Tracey Young & Ben Hout & John Brazier - 11-19 International Regulations and Recommendations for Utility Data for Health Technology Assessment
by Donna Rowen & Ismail Azzabi Zouraq & Helene Chevrou-Severac & Ben Hout - 21-31 A Review of Generic Preference-Based Measures for Use in Cost-Effectiveness Models
by John Brazier & Roberta Ara & Donna Rowen & Helene Chevrou-Severac - 33-41 The Role of Condition-Specific Preference-Based Measures in Health Technology Assessment
by Donna Rowen & John Brazier & Roberta Ara & Ismail Azzabi Zouraq - 43-55 The Identification, Review and Synthesis of Health State Utility Values from the Literature
by Roberta Ara & John Brazier & Tessa Peasgood & Suzy Paisley - 57-66 The Use of Mapping to Estimate Health State Utility Values
by Roberta Ara & Donna Rowen & Clara Mukuria - 67-75 Recommended Methods for the Collection of Health State Utility Value Evidence in Clinical Studies
by Roberta Ara & John Brazier & Tracey Young - 77-88 The Use of Health State Utility Values in Decision Models
by Roberta Ara & John Brazier & Ismail Azzabi Zouraq - 89-94 Estimating Health State Utility Values for Comorbidities
by Roberta Ara & John Brazier
January 2017, Volume 35, Issue 1
- 1-4 Measuring the Value of Pharmaceuticals in the US Health System
by Surrey M. Walton & Anirban Basu & John Mullahy & Samuel Hong & Glen T. Schumock - 5-13 Discounting the Recommendations of the Second Panel on Cost-Effectiveness in Health and Medicine
by Mike Paulden & James F. O’Mahony & Christopher McCabe - 15-24 Modeling Treatment Sequences in Pharmacoeconomic Models
by Ying Zheng & Feng Pan & Sonja Sorensen - 25-42 The Societal Cost of Schizophrenia: A Systematic Review
by Huajie Jin & Iris Mosweu - 43-63 Systematic Review and Quality Appraisal of Cost-Effectiveness Analyses of Pharmacologic Maintenance Treatment for Chronic Obstructive Pulmonary Disease: Methodological Considerations and Recommendations
by Simon van der Schans & Lucas M. A. Goossens & Melinde R. S. Boland & Janwillem W. H. Kocks & Maarten J. Postma & Job F. M. van Boven & Maureen P. M. H. Rutten-van Mölken - 65-82 Challenges in Cost-Effectiveness Analysis Modelling of HPV Vaccines in Low- and Middle-Income Countries: A Systematic Review and Practice Recommendations
by Obinna I. Ekwunife & James F. O’Mahony & Andreas Gerber Grote & Christoph Mosch & Tatjana Paeck & Stefan K. Lhachimi - 83-95 Economic Evaluations of First-Line Chemotherapy Regimens for Pancreatic Cancer: A Critical Review
by Mahdi Gharaibeh & J. Lyle Bootman & Ali McBride & Jennifer Martin & Ivo Abraham - 97-109 Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Paul Tappenden & Sue Harnan & Shijie Ren & Praveen Thokala & Ruth Wong & Clara Mukuria & Clare Green & Simon Pledge & John Tidy - 111-124 Mapping Between the Sydney Asthma Quality of Life Questionnaire (AQLQ-S) and Five Multi-Attribute Utility Instruments (MAUIs)
by Billingsley Kaambwa & Gang Chen & Julie Ratcliffe & Angelo Iezzi & Aimee Maxwell & Jeff Richardson - 125-128 Benefits, Challenges and Potential Strategies of Open Source Health Economic Models
by William C. N. Dunlop & Nicola Mason & James Kenworthy & Ron L. Akehurst
December 2016, Volume 34, Issue 12
- 1195-1209 Using Best–Worst Scaling to Investigate Preferences in Health Care
by Kei Long Cheung & Ben F. M. Wijnen & Ilene L. Hollin & Ellen M. Janssen & John F. Bridges & Silvia M. A. A. Evers & Mickael Hiligsmann - 1211-1225 Cost Effectiveness of Pneumococcal Vaccination in Children in Low- and Middle-Income Countries: A Systematic Review
by Surasak Saokaew & Ajaree Rayanakorn & David Bin-Chia Wu & Nathorn Chaiyakunapruk - 1227-1239 The Value of Medicines: A Crucial but Vague Concept
by Fernando Antoñanzas & Robert Terkola & Maarten Postma - 1241-1253 Vedolizumab for Treating Moderately to Severely Active Crohn’s Disease After Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Rachid Rafia & Alison Scope & Sue Harnan & John W. Stevens & Matt Stevenson & Alan Lobo - 1255-1265 Assessing the Value of Treatment to Address Various Symptoms Associated with Multiple Sclerosis: Results from a Contingent Valuation Study
by Pei-Jung Lin & Cayla J. Saret & Peter J. Neumann & Eileen A. Sandberg & Joshua T. Cohen - 1267-1276 The Pharmacoeconomic Evaluation Process in Ireland
by Laura McCullagh & Michael Barry - 1277-1297 Nocturia Work Productivity and Activity Impairment Compared with Other Common Chronic Diseases
by Paul S. J. Miller & Harry Hill & Fredrik L. Andersson - 1299-1308 Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model
by Christiaan Dolk & Martin Eichner & Robert Welte & Anastassia Anastassopoulou & Laure-Anne Van Bellinghen & Barbara Poulsen Nautrup & Ilse Van Vlaenderen & Ruprecht Schmidt-Ott & Markus Schwehm & Maarten Postma
November 2016, Volume 34, Issue 11
- 1071-1074 From Good to Better: New Dutch Guidelines for Economic Evaluations in Healthcare
by Matthijs Versteegh & Saskia Knies & Werner Brouwer - 1075-1086 Estimating Marginal Healthcare Costs Using Genetic Variants as Instrumental Variables: Mendelian Randomization in Economic Evaluation
by Padraig Dixon & George Davey Smith & Stephanie von Hinke & Neil M. Davies & William Hollingworth - 1087-1100 Economic and Humanistic Burden of Osteoarthritis: A Systematic Review of Large Sample Studies
by Feng Xie & Bruno Kovic & Xuejing Jin & Xiaoning He & Mengxiao Wang & Camila Silvestre - 1101-1110 The Clinical and Cost Effectiveness of Apremilast for Treating Active Psoriatic Arthritis: A Critique of the Evidence
by Eleftherios Sideris & Mark Corbett & Stephen Palmer & Nerys Woolacott & Laura Bojke - 1111-1131 A Methodological Review of US Budget-Impact Models for New Drugs
by Josephine Mauskopf & Stephanie Earnshaw - 1133-1144 Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple Sclerosis
by Matthijs Versteegh - 1145-1159 Cost Effectiveness of Characterised Chondrocyte Implantation for Treatment of Cartilage Defects of the Knee in the UK
by Jamie Elvidge & Ash Bullement & Anthony J. Hatswell - 1161-1172 Reporting Guidelines for the Use of Expert Judgement in Model-Based Economic Evaluations
by Cynthia P. Iglesias & Alexander Thompson & Wolf H. Rogowski & Katherine Payne - 1173-1186 Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience
by François Bocquet & Anaïs Loubière & Isabelle Fusier & Anne-Laure Cordonnier & Pascal Paubel - 1187-1188 Discretely Integrated Condition Event Simulation for Pharmacoeconomics
by Mondher Toumi & Ekkehard Beck & Steve Sherman & Leyla Mohseninejad & Samuel Aballéa - 1189-1190 Response to Letter to the Editor Regarding Discretely Integrated Condition Event Simulation for Pharmacoeconomics
by J. Jaime Caro
October 2016, Volume 34, Issue 10
- 967-969 Performance-Based Agreements in Italy: ‘Trendy Outcomes’ or Mere Illusions?
by Livio Garattini & Alessandro Curto - 971-980 Sustainable Financing of Innovative Therapies: A Review of Approaches
by Aidan Hollis - 981-992 Daclatasvir for the Treatment of Chronic Hepatitis C: A Critique of the Clinical and Economic Evidence
by Alexis Llewellyn & Rita Faria & Beth Woods & Mark Simmonds & James Lomas & Nerys Woolacott & Susan Griffin - 993-1004 EuroQol Protocols for Time Trade-Off Valuation of Health Outcomes
by Mark Oppe & Kim Rand-Hendriksen & Koonal Shah & Juan M. Ramos‐Goñi & Nan Luo - 1005-1014 The Effects of Diagnostic Definitions in Claims Data on Healthcare Cost Estimates: Evidence from a Large-Scale Panel Data Analysis of Diabetes Care in Japan
by Haruhisa Fukuda & Shunya Ikeda & Takeru Shiroiwa & Takashi Fukuda - 1015-1022 Using Linear Equating to Map PROMIS® Global Health Items and the PROMIS-29 V2.0 Profile Measure to the Health Utilities Index Mark 3
by Ron D. Hays & Dennis A. Revicki & David Feeny & Peter Fayers & Karen L. Spritzer & David Cella - 1023-1038 A Model-Based Economic Evaluation of Biologic and Non-Biologic Options for the Treatment of Adults with Moderately-to-Severely Active Ulcerative Colitis after the Failure of Conventional Therapy
by Paul Tappenden & Shijie Ren & Rachel Archer & Rebecca Harvey & Marrissa Martyn-St James & Hasan Basarir & John Stevens & Alan Lobo & Sami Hoque - 1039-1050 Real-World Evidence: A Comparison of the Australian Herceptin Program and Clinical Trials of Trastuzumab for HER2-Positive Metastatic Breast Cancer
by Bonny Parkinson & Rosalie Viney & Marion Haas & Stephen Goodall & Preeyaporn Srasuebkul & Sallie-Anne Pearson - 1051-1065 BEACON: A Summary Framework to Overcome Potential Reimbursement Hurdles
by William C. N. Dunlop & C. Daniel Mullins & Olaf Pirk & Ron Goeree & Maarten J. Postma & Ashley Enstone & Louise Heron - 1067-1070 Publication of Cost-of-Illness Studies: Does Methodological Complexity Matter?
by T. Joseph Mattingly & C. Daniel Mullins & Eberechukwu Onukwugha
September 2016, Volume 34, Issue 9
- 829-831 Model Validation: Has it’s Time Come?
by Jonathan Karnon - 833-845 Unremarked or Unperformed? Systematic Review on Reporting of Validation Efforts of Health Economic Decision Models in Seasonal Influenza and Early Breast Cancer
by Pieter T. Boer & Geert W. J. Frederix & Talitha L. Feenstra & Pepijn Vemer - 847-861 Cost Effectiveness of HPV Vaccination: A Systematic Review of Modelling Approaches
by Joshua Pink & Ben Parker & Stavros Petrou - 901-912 The Clinical and Cost Effectiveness of Vortioxetine for the Treatment of a Major Depressive Episode in Patients With Failed Prior Antidepressant Therapy: A Critique of the Evidence
by James Lomas & Alexis Llewellyn & Marta Soares & Mark Simmonds & Kath Wright & Alison Eastwood & Stephen Palmer - 913-923 Extended Cost-Effectiveness Analysis for Health Policy Assessment: A Tutorial
by Stéphane Verguet & Jane J. Kim & Dean T. Jamison - 925-937 Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in Ireland
by Susanne Schmitz & Laura McCullagh & Roisin Adams & Michael Barry & Cathal Walsh - 939-951 The Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in Finland
by Lisa Nagy & Terho Heikkinen & Alfred Sackeyfio & Richard Pitman - 953-966 Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting
by Melanie J. Davies & Divina Glah & Barrie Chubb & Gerasimos Konidaris & Phil McEwan
August 2016, Volume 34, Issue 8
- 723-731 Economic Evaluation of Vaccination Programmes in Older Adults and the Elderly: Important Issues and Challenges
by Sevan Dirmesropian & James G. Wood & C. Raina MacIntyre & Philippe Beutels & Anthony T. Newall - 741-750 Ledipasvir-Sofosbuvir for Treating Chronic Hepatitis C: A NICE Single Technology Appraisal—An Evidence Review Group Perspective
by P. Thokala & E. L. Simpson & P. Tappenden & J. W. Stevens & K. Dickinson & S. Ryder & P. Harrison - 805-814 The Impact of Different DCE-Based Approaches When Anchoring Utility Scores
by Richard Norman & Brendan Mulhern & Rosalie Viney - 815-827 Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria
by Jonathan Graham & Doreen McBride & Donald Stull & Anna Halliday & Stamatia Theodora Alexopoulos & Maria-Magdalena Balp & Matthew Griffiths & Ion Agirrezabal & Torsten Zuberbier & Alan Brennan
July 2016, Volume 34, Issue 7
- 625-627 Why Cancer?
by Alan Haycox - 635-644 Cost Implications of Value-Based Pricing for Companion Diagnostic Tests in Precision Medicine
by Gregory S. Zaric - 645-649 Health, Health-Related Quality of Life, and Quality of Life: What is the Difference?
by Milad Karimi & John Brazier - 651-664 Economic Evaluation of Mental Health Interventions: A Guide to Costing Approaches
by James Shearer & Paul McCrone & Renee Romeo - 673-680 Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Hazel Squires & Matt Stevenson & Emma Simpson & Rebecca Harvey & John Stevens - 681-707 Systematic Review of Model-Based Economic Evaluations of Treatments for Alzheimer’s Disease
by Luis Hernandez & Asli Ozen & Rodrigo DosSantos & Denis Getsios - 709-721 Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia
by Krithika Rajagopalan & David Trueman & Lydia Crowe & Daniel Squirrell & Antony Loebel
June 2016, Volume 34, Issue 6
- 529-531 Can Clinical Guidelines Afford to Ignore Cost Effectiveness? An Ethical Perspective
by Kenneth Boyd & Peter Hall - 533-550 Systematic Review of the Economic Burden of Pulmonary Arterial Hypertension
by Shuyan Gu & Huimei Hu & Hengjin Dong - 551-567 Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals
by Jagpreet Chhatwal & Tianhua He & Maria A. Lopez-Olivo - 569-585 A Systematic Review of Cost-Effectiveness Models in Type 1 Diabetes Mellitus
by Martin Henriksson & Ramandeep Jindal & Catarina Sternhufvud & Klas Bergenheim & Elisabeth Sörstadius & Michael Willis - 587-596 Apremilast for the Treatment of Moderate to Severe Plaque Psoriasis: A Critique of the Evidence
by Sebastian Hinde & Ros Wade & Stephen Palmer & Nerys Woolacott & Eldon Spackman - 597-608 Identification of Evidence for Key Parameters in Decision-Analytic Models of Cost Effectiveness: A Description of Sources and a Recommended Minimum Search Requirement
by Suzy Paisley - 609-616 Biosimilars: How Can Payers Get Long-Term Savings?
by Jorge Mestre-Ferrandiz & Adrian Towse & Mikel Berdud - 617-624 Exploring Uncertainty in Economic Evaluations of Drugs and Medical Devices: Lessons from the First Review of Manufacturers’ Submissions to the French National Authority for Health
by Salah Ghabri & Françoise F. Hamers & Jean Michel Josselin
May 2016, Volume 34, Issue 5
- 423-426 Pharmaceutical Price Schemes in Europe: Time for a ‘Continental’ One?
by Livio Garattini & Alessandro Curto & Nick Freemantle - 427-433 Assessing the Value of New Treatments for Hepatitis C: Are International Decision Makers Getting this Right?
by Beth Woods & Rita Faria & Susan Griffin - 435-446 Value-Based Assessment of New Medical Technologies: Towards a Robust Methodological Framework for the Application of Multiple Criteria Decision Analysis in the Context of Health Technology Assessment
by Aris Angelis & Panos Kanavos - 447-461 Conducting Economic Evaluations Alongside Randomised Trials: Current Methodological Issues and Novel Approaches
by Dyfrig Hughes & Joanna Charles & Dalia Dawoud & Rhiannon Tudor Edwards & Emily Holmes & Carys Jones & Paul Parham & Catrin Plumpton & Colin Ridyard & Huw Lloyd-Williams & Eifiona Wood & Seow Tien Yeo - 463-477 Rivaroxaban for Preventing Atherothrombotic Events in People with Acute Coronary Syndrome and Elevated Cardiac Biomarkers: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Abdullah Pandor & Daniel Pollard & Tim Chico & Robert Henderson & Matt Stevenson - 479-498 Economic Burden and Quality-of-Life Effects of Chronic Lymphocytic Leukemia: A Systematic Review of the Literature
by Simon Frey & Carl R. Blankart & Tom Stargardt - 499-508 Complex Valuation: Applying Ideas from the Complex Intervention Framework to Valuation of a New Measure for End-of-Life Care
by Joanna Coast & Elisabeth Huynh & Philip Kinghorn & Terry Flynn - 509-520 Cost Effectiveness of First-Line Oral Therapies for Pulmonary Arterial Hypertension: A Modelling Study
by Kathryn Coyle & Doug Coyle & Julie Blouin & Karen Lee & Mohammed F. Jabr & Khai Tran & Lisa Mielniczuk & John Swiston & Mike Innes - 521-527 EQ-5D Utilities in Chronic Spontaneous/Idiopathic Urticaria
by Emma Hawe & Doreen McBride & Maria-Magdalena Balp & Haijun Tian & Anna Halliday & Donald E. Stull
April 2016, Volume 34, Issue 4
- 323-329 Should the Lambda (λ) Remain Silent?
by Hossein Haji Ali Afzali & Jonathan Karnon & Mark Sculpher - 331-332 Richard Edlin, Christopher McCabe, Claire Hulme, Peter Hall, Judy Wright: Cost Effectiveness Modelling for Health Technology Assessment: A Practical Course
by Doug Coyle - 333-336 Do Pills Have No Ills? Capturing the Impact of Direct Treatment Disutility
by Alexander Thompson & Bruce Guthrie & Katherine Payne - 337-348 The Clinical and Cost Effectiveness of Ustekinumab for the Treatment of Psoriatic Arthritis: A Critique of the Evidence
by Joanne O’Connor & Stephen Rice & Alison Smith & Mark Rodgers & Rocio Rodriguez Lopez & Dawn Craig & Nerys Woolacott - 349-361 AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Users
by P. Vemer & I. Corro Ramos & G. A. K. Voorn & M. J. Al & T. L. Feenstra - 363-391 Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France
by Sylvain Druais & Agathe Doutriaux & Magali Cognet & Annabelle Godet & Christophe Lançon & Pierre Levy & Ludovic Samalin & Pascal Guillon - 393-402 What Can We Expect from Value-Based Funding of Medicines? A Retrospective Study
by Anthony Harris & Jing Jing Li & Karen Yong - 403-417 Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa
by Ilanca Fraser & Johanita Burger & Martie Lubbe & George Dranitsaris & Mark Sonderup & Tienie Stander - 419-420 Comment on: “Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review”
by Angelo Claudio Palozzo & Andrea Messori - 421-422 Authors’ Reply to Palozzo and Messori: ‘‘Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review’’
by Bonny Parkinson & Adam G. Elshaug
March 2016, Volume 34, Issue 3
- 217-220 PCSK9 Inhibitors: A Technology Worth Paying For?
by William S. Weintraub & Samuel S. Gidding - 217-220 PCSK9 Inhibitors: A Technology Worth Paying For?
by William Weintraub & Samuel Gidding - 221-224 Economic Evidence of Pneumococcal Vaccination in Older Adults: Uncertain Modelling or Competitive Tendering?
by Livio Garattini & Anna Padula & Milene Costa - 221-224 Economic Evidence of Pneumococcal Vaccination in Older Adults: Uncertain Modelling or Competitive Tendering?
by Livio Garattini & Anna Padula & Milene Rangel Costa - 225-226 Zaheer-Ud-Din Babar (ed): Pharmaceutical Prices in the 21st Century
by Suzanne Rose Hill - 225-226 Zaheer-Ud-Din Babar (ed): Pharmaceutical Prices in the 21st Century
by Suzanne Hill - 227-244 Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community
by Bernhard Ultsch & Oliver Damm & Philippe Beutels & Joke Bilcke & Bernd Brüggenjürgen & Andreas Gerber-Grote & Wolfgang Greiner & Germaine Hanquet & Raymond Hutubessy & Mark Jit & Mirjam Knol & Rüdiger Kries & Alexander Kuhlmann & Daniel Levy-Bruhl & Matthias Perleth & Maarten Postma & Heini Salo & Uwe Siebert & Jürgen Wasem & Ole Wichmann - 227-244 Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community
by Bernhard Ultsch & Oliver Damm & Philippe Beutels & Joke Bilcke & Bernd Brüggenjürgen & Andreas Gerber-Grote & Wolfgang Greiner & Germaine Hanquet & Raymond Hutubessy & Mark Jit & Mirjam Knol & Rüdiger Kries & Alexander Kuhlmann & Daniel Levy-Bruhl & Matthias Perleth & Maarten Postma & Heini Salo & Uwe Siebert & Jürgen Wasem & Ole Wichmann - 245-257 Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Munira Essat & Paul Tappenden & Shijie Ren & Alice Bessey & Rachel Archer & Ruth Wong & Alan Lobo & Sami Hoque - 245-257 Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Munira Essat & Paul Tappenden & Shijie Ren & Alice Bessey & Rachel Archer & Ruth Wong & Alan Lobo & Sami Hoque - 259-272 Cost-Effectiveness Models in Age-Related Macular Degeneration: Issues and Challenges
by Jordana K. Schmier & Carolyn K. Hulme-Lowe - 259-272 Cost-Effectiveness Models in Age-Related Macular Degeneration: Issues and Challenges
by Jordana Schmier & Carolyn Hulme-Lowe - 273-284 Are Efficient Designs Used in Discrete Choice Experiments Too Difficult for Some Respondents? A Case Study Eliciting Preferences for End-of-Life Care
by Terry N. Flynn & Marcel Bilger & Chetna Malhotra & Eric A. Finkelstein - 273-284 Are Efficient Designs Used in Discrete Choice Experiments Too Difficult for Some Respondents? A Case Study Eliciting Preferences for End-of-Life Care
by Terry Flynn & Marcel Bilger & Chetna Malhotra & Eric Finkelstein - 285-301 Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation
by Monika Wagner & Hanane Khoury & Jacob Willet & Donna Rindress & Mireille Goetghebeur - 285-301 Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation
by Monika Wagner & Hanane Khoury & Jacob Willet & Donna Rindress & Mireille Goetghebeur - 303-314 Budget Impact Analysis of Using Dihydroartemisinin–Piperaquine to Treat Uncomplicated Malaria in Children in Tanzania
by Amani Mori & Ole Norheim & Bjarne Robberstad - 303-314 Budget Impact Analysis of Using Dihydroartemisinin–Piperaquine to Treat Uncomplicated Malaria in Children in Tanzania
by Amani Thomas Mori & Ole Frithjof Norheim & Bjarne Robberstad - 315-322 Use of Value of Information in Healthcare Decision Making: Exploring Multiple Perspectives
by Jill Bindels & Bram Ramaekers & Isaac Ramos & Leyla Mohseninejad & Saskia Knies & Janneke Grutters & Maarten Postma & Maiwenn Al & Talitha Feenstra & Manuela Joore - 315-322 Use of Value of Information in Healthcare Decision Making: Exploring Multiple Perspectives
by Jill Bindels & Bram Ramaekers & Isaac Corro Ramos & Leyla Mohseninejad & Saskia Knies & Janneke Grutters & Maarten Postma & Maiwenn Al & Talitha Feenstra & Manuela Joore
February 2016, Volume 34, Issue 2
- 91-93 Big Data and Its Role in Health Economics and Outcomes Research: A Collection of Perspectives on Data Sources, Measurement, and Analysis
by Eberechukwu Onukwugha - 91-93 Big Data and Its Role in Health Economics and Outcomes Research: A Collection of Perspectives on Data Sources, Measurement, and Analysis
by Eberechukwu Onukwugha - 95-100 Specification Issues in a Big Data Context: Controlling for the Endogeneity of Consumer and Provider Behaviours in Healthcare Treatment Effects Models
by William H. Crown - 95-100 Specification Issues in a Big Data Context: Controlling for the Endogeneity of Consumer and Provider Behaviours in Healthcare Treatment Effects Models
by William Crown - 101-106 Big Data and Health Economics: Strengths, Weaknesses, Opportunities and Threats
by Brendan Collins - 107-114 NETIMIS: Dynamic Simulation of Health Economics Outcomes Using Big Data
by Owen Johnson & Peter Hall & Claire Hulme - 107-114 NETIMIS: Dynamic Simulation of Health Economics Outcomes Using Big Data
by Owen A. Johnson & Peter S. Hall & Claire Hulme - 115-126 Transforming Healthcare Delivery: Integrating Dynamic Simulation Modelling and Big Data in Health Economics and Outcomes Research
by Deborah Marshall & Lina Burgos-Liz & Kalyan Pasupathy & William Padula & Maarten IJzerman & Peter Wong & Mitchell Higashi & Jordan Engbers & Samuel Wiebe & William Crown & Nathaniel Osgood - 115-126 Transforming Healthcare Delivery: Integrating Dynamic Simulation Modelling and Big Data in Health Economics and Outcomes Research
by Deborah A. Marshall & Lina Burgos-Liz & Kalyan S. Pasupathy & William V. Padula & Maarten J. IJzerman & Peter K. Wong & Mitchell K. Higashi & Jordan Engbers & Samuel Wiebe & William Crown & Nathaniel D. Osgood - 127-138 National Database for Autism Research (NDAR): Big Data Opportunities for Health Services Research and Health Technology Assessment
by Nalin Payakachat & J. Mick Tilford & Wendy J. Ungar - 127-138 National Database for Autism Research (NDAR): Big Data Opportunities for Health Services Research and Health Technology Assessment
by Nalin Payakachat & J. Tilford & Wendy Ungar - 139-154 Realising the Value of Linked Data to Health Economic Analyses of Cancer Care: A Case Study of Cancer 2015
by Paula K. Lorgelly & Brett Doble & Rachel J. Knott - 139-154 Realising the Value of Linked Data to Health Economic Analyses of Cancer Care: A Case Study of Cancer 2015
by Paula Lorgelly & Brett Doble & Rachel Knott